The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01171768|
Recruitment Status : Completed
First Posted : July 28, 2010
Last Update Posted : July 21, 2011
|Condition or disease|
|Inflammatory Lung Diseases Hemoptysis|
|Study Type :||Observational|
|Estimated Enrollment :||52 participants|
|Observational Model:||Case Control|
|Official Title:||The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis|
|Study Start Date :||June 2008|
|Study Completion Date :||December 2010|
|patients with hemoptysis within 2 weeks|
|patients without hemoptysis within 2 years|
- serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis [ Time Frame: up to 7 days after enrollment ]We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.
- to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia. [ Time Frame: up to 7 days after enrollment ]We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01171768
|Korea, Republic of|
|Samsung Medical Center|
|Seoul, Korea, Republic of|